Neumora Therapeutics, an early-stage neuroscience drug development company, focuses on three key areas, alzheimer's agitation, schizophrenia and obesity. The company has three lead candidates, all oral drugs, with early stage clinical trial read-outs, by the end of 2026.
Financial Statistics:
- $147 million cash
- 180 million diluted shares outstanding
- 270 million market cap
Intellectual Property:
- NMRA - 511 Alzheimer's Agitation, Expected to expire into 2046
- NMRA - 898 Schizophrenia, Expected to expire in 2044
- NMRA - 215 Obesity, Expected to expire in 2043
Timeline Catalyst:
- NMRA-511: Multiple ascending dose completion in the fourth quarter 2026
- NMRA-898: Phase 2 data 2H of 2026
- NMRA-215: Start clinical trials by end of 2026
Neumora is a clinical stage biotech company focused on three areas of unmet need. The stock is priced at $1.50 per share (penny stock), meaning less than $5.00. There are many risks to investing in this company. Thank you for reading.
Disclaimer: This stock, or any other stock referenced on this site, is for purely educational purposes. Please consult with your investment professional, prior to buying stocks, precious metals, or commodity's.
